|Day Low/High||0.10 / 0.12|
|52 Wk Low/High||0.05 / 0.38|
Company anticipates announcing topline efficacy and safety results in July 2019
SAN JOSE, Calif., Feb.
Dr. R. Todd Plott, developer of SOLODYN™, ZIANA™, and NORITATE™, becomes company's third independent director
MENLO PARK, Calif., Nov.
Trial will evaluate 1% concentration of minocycline carried by company's patented HyantX™ delivery system
Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.
These under-$10 stocks are within range of triggering breakout trades. Here's how to play them.
BioPharmX (BPMX) reported successful results from a safety study of its topical gel medication for acne, BPX-01, on Monday.
Here's a technical look at how to trade five biotech stocks that are setting up to break out and trade much higher.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: APEI, OI, ZPIN Downgrades: DFRG Initiations: BPMX, FTAI, KEN, NYLD, RKDA Read on to get TheStreet Quant Ratings' detailed report:
BioPharmX stock is rising on heavy trading volume on Monday after the pharmaceutical company said it may have developed a breakthrough treatment for acne.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.